The landscape of treatment for renal cell carcinoma has changed radically over the last few years. Previously, the most effective treatments were too toxic, too expensive or too ineffective. Careful biological studies have uncovered pathways relevant to the survival, growth and spread of renal cell carcinoma and other cancers, and have highlighted rational targets for therapy. New agents aimed at these targets have been shown to be highly effective, but have brought with them a new range of toxicities and other complexities in the management of our patients. This review describes three drugs recently approved in Australia for use in advanced renal cell carcinoma and other agents of ciinical and research interest.
|Number of pages||4|
|Publication status||Published - 1 Nov 2008|